Interaction of 14-3-3 proteins with the Estrogen Receptor Alpha F domain provides a drug target interface

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 22, 2013, Pages 8894-8899

  De Vries van Leeuwen, Ingrid J ^a   Da Costa Pereira, Daniel ^a   Flach, Koen D ^b   Piersma, Sander R ^c   Haase, Christian ^d   Bier, David ^e   Yalcin, Zeliha ^a   Michalides, Rob ^b   Feenstra, K Anton ^a   Jiménez, Connie R ^c   De Greef, Tom F A ^d   Brunsveld, Luc ^d   Ottmann, Christian ^d,e   Zwart, Wilbert ^b   De Boer, Albertus H ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^e CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FUSICOCCIN; PROTEIN 14 3 3; THREONINE;

ARTICLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMATIN; CONTROLLED STUDY; CRYSTALLIZATION; DIMERIZATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

14-3-3 PROTEINS; AMINO ACID SEQUENCE; BREAST NEOPLASMS; CRYSTALLIZATION; DIMERIZATION; DRUG DELIVERY SYSTEMS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLUORESCENCE POLARIZATION; GENE COMPONENTS; GENE EXPRESSION REGULATION; GLYCOSIDES; HUMANS; MASS SPECTROMETRY; MCF-7 CELLS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN ISOFORMS; SEQUENCE ALIGNMENT;

EID: 84878442899     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220809110     Document Type: Article

References (44)

1. Ariazi EA, Ariazi JL, Cordera F, Jordan VC (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6(3):181-202.
2. Asselin-Labat M-L, et al. (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299):798-802.
3. Bergamaschi A, Katzenellenbogen BS (2012) Tamoxifen downregulation of miR-451 increases 14-3-3? and promotes breast cancer cell survival and endocrine resistance. Oncogene 31(1):39-47.
4. ZwartW, et al. (2007) PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J 26(15):3534-3544.
5. Shanle EK, XuW (2010) Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev 62(13):1265-1276.
6. Wardell SE, Marks JR, McDonnell DP (2011) The turnover of estrogen receptor a by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 82(2):122-130.
7. Carraz M, Zwart W, Phan T, Michalides R, Brunsveld L (2009) Perturbation of estrogen receptor alpha localization with synthetic nona-arginine LXXLL-peptide coactivator binding inhibitors. Chem Biol 16(7):702-711.
8. Powell E, Wang Y, Shapiro DJ, Xu W (2010) Differential requirements of Hsp90 and DNA for the formation of estrogen receptor homodimers and heterodimers. J Biol Chem 285(21):16125-16134.
9. Zhang YH, Li ZG, Sacks DB, Ames JB (2012) Structural basis for Ca2+-induced activation and dimerization of estrogen receptor a by calmodulin. J Biol Chem 287(12):9336-9344.
10. Brzozowski AM, et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389(6652):753-758.
11. Mahalingam D, et al. (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100(10): 1523-1529.
12. Fliss AE, Benzeno S, Rao J, Caplan AJ (2000) Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol 72(5):223-230.
13. Helsen C, et al. (2012) Structural basis for nuclear hormone receptor DNA binding. Mol Cell Endocrinol 348(2):411-417.
14. Powell E, Xu W (2008) Intermolecular interactions identify ligand-selective activity of estrogen receptor alpha/beta dimers. Proc Natl Acad Sci USA 105(48):19012-19017.
15. Peters GA, Khan SA (1999) Estrogen receptor domains E and F: Role in dimerization and interaction with coactivator RIP-140. Mol Endocrinol 13(2):286-296.
16. Skafar DF, Zhao CQ (2008) The multifunctional estrogen receptor-alpha F domain. Endocrine 33(1):1-8.
17. Yang J, SingletonDW, Shaughnessy EA, Khan SA (2008) The F-domain of estrogen receptoralpha inhibits ligand induced receptor dimerization. Mol Cell Endocrinol 295(1-2):94-100.
18. Ballio A, et al. (1964) Fusicoccin: A New Wilting Toxin produced by Fusicoccum amygdali Del. Nature 203(4942):297.
19. de Vries-van Leeuwen IJ, et al. (2010) Fusicoccin-A selectively induces apoptosis in tumor cells after interferon-alpha priming. Cancer Lett 293(2):198-206.
20. Korthout HA, de Boer AH (1994) A fusicoccin binding protein belongs to the family of 14-3-3 brain protein homologs. Plant Cell 6(11):1681-1692.
21. Würtele M, Jelich-Ottmann C, Wittinghofer A, Oecking C (2003) Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J 22(5):987-994.
22. Ottmann C, et al. (2007) Structure of a 14-3-3 coordinated hexamer of the plant plasma membrane H+-ATPase by combining X-ray crystallography and electron cryomicroscopy. Mol Cell 25(3):427-440.
23. Morrison DK (2009) The 14-3-3 proteins: Integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19(1):16-23.
24. Steinacker P, Aitken A, Otto M (2011) 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 22(7):696-704.
25. Jahn T, et al. (1997) The 14-3-3 protein interacts directly with the C-terminal region of the plant plasma membrane H(+)-ATPase. Plant Cell 9(10):1805-1814.
26. Tanenbaum DM, Wang Y, Williams SP, Sigler PB (1998) Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 95(11):5998-6003.
27. Wu M, et al. (2006) SWTY-a general peptide probe for homogeneous solution binding assay of 14-3-3 proteins. Anal Biochem 349(2):186-196.
28. Ballio A, et al. (1991) H-1-NMR conformational study of Fusicoccin and related compounds-molecular conformation and biological activity. Phytochemistry 30(1):137-146.
29. Zwart W, et al. (2011) Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer. EMBO J 30(23):4764-4776.
30. Kallio A, et al. (2008) Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol Cell Endocrinol 289(1-2):38-48.
31. Fuglsang AT, et al. (2003) The binding site for regulatory 14-3-3 protein in plant plasma membrane H+-ATPase: Involvement of a region promoting phosphorylationindependent interaction in addition to the phosphorylation- dependent C-terminal end. J Biol Chem 278(43):42266-42272.
32. Jelich-Ottmann C, Weiler EW, Oecking C (2001) Binding of regulatory 14-3-3 proteins to the C terminus of the plant plasma membrane H+-ATPpase involves part of its autoinhibitory region. J Biol Chem 276(43):39852-39857.
33. Zwart W, Theodorou V, Carroll JS (2011) Estrogen receptor-positive breast cancer: A multidisciplinary challenge. Wiley Interdiscip Rev Syst Biol Med 3(2):216-230.
34. Shapiro DJ, Mao C, Cherian MT (2011) Small molecule inhibitors as probes for estrogen and androgen receptor action. J Biol Chem 286(6):4043-4048.
35. Nilsson S, Koehler KF, Gustafsson JA (2011) Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 10(10):778-792.
36. Moore TW, Mayne CG, Katzenellenbogen JA (2010) Minireview: Not picking pockets: Nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 24(4):683-695.
37. Koide A, et al. (2007) Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions. Mol Endocrinol 21(4):829-842.
38. de Boer AH, van Kleeff PJ, Gao J (2013) Plant 14-3-3 proteins as spiders in a web of phosphorylation. Protoplasma 250(2):425-440.
39. Olsson A, Svennelid F, Ek B, Sommarin M, Larsson C (1998) A phosphothreonine residue at the C-terminal end of the plasma membrane H+-ATPase is protected by fusicoccin-induced 14-3-3 binding. Plant Physiol 118(2):551-555.
40. Kinoshita T, Shimazaki K (2001) Analysis of the phosphorylation level in guard-cell plasma membrane H+-ATPase in response to fusicoccin. Plant Cell Physiol 42(4):424-432.
41. Bartella V, et al. (2012) Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter. Breast Cancer Res Treat 134(2):569-581.
42. Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 73(11):1039-1051.
43. de Boer AH, de Vries-van Leeuwen IJ (2012) Fusicoccanes: Diterpenes with surprising biological functions. Trends Plant Sci 17(6):360-368.
44. Schoonheim PJ, et al. (2007) 14-3-3 adaptor proteins are intermediates in ABA signal transduction during barley seed germination. Plant J 49(2):289-301.